<SEC-DOCUMENT>0001628280-23-015996.txt : 20230505
<SEC-HEADER>0001628280-23-015996.hdr.sgml : 20230505
<ACCEPTANCE-DATETIME>20230505081623
ACCESSION NUMBER:		0001628280-23-015996
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		15
CONFORMED PERIOD OF REPORT:	20230505
ITEM INFORMATION:		Results of Operations and Financial Condition
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20230505
DATE AS OF CHANGE:		20230505

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Ovid Therapeutics Inc.
		CENTRAL INDEX KEY:			0001636651
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				465270895
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-38085
		FILM NUMBER:		23891390

	BUSINESS ADDRESS:	
		STREET 1:		441 NINTH AVENUE, 14TH FLOOR
		CITY:			NEW YORK
		STATE:			NY
		ZIP:			10001
		BUSINESS PHONE:		212-776-4381

	MAIL ADDRESS:	
		STREET 1:		441 NINTH AVENUE, 14TH FLOOR
		CITY:			NEW YORK
		STATE:			NY
		ZIP:			10001
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>ovid-20230505.htm
<DESCRIPTION>8-K
<TEXT>
<XBRL>
<?xml version="1.0" ?><!--XBRL Document Created with Wdesk from Workiva--><!--Copyright 2023 Workiva--><!--r:49487af2-aa3d-46a1-bf94-ce7758f1a580,g:6ad0f39e-08b7-480f-9056-de0fc16a9d03,d:6312be7cbcba47668c6ee367de95a042--><html xmlns="http://www.w3.org/1999/xhtml" xmlns:dei="http://xbrl.sec.gov/dei/2022" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2020-02-12" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xml:lang="en-US"><head><meta http-equiv="Content-Type" content="text/html"/>


<title>ovid-20230505</title></head><body><div style="display:none"><ix:header><ix:hidden><ix:nonNumeric contextRef="i3959c496a69e480bb832a8e8833578c0_D20230505-20230505" name="dei:EntityCentralIndexKey" id="id3VybDovL2RvY3MudjEvZG9jOjYzMTJiZTdjYmNiYTQ3NjY4YzZlZTM2N2RlOTVhMDQyL3NlYzo2MzEyYmU3Y2JjYmE0NzY2OGM2ZWUzNjdkZTk1YTA0Ml80L2ZyYWc6NzZjMThlNWFiNjY2NDk1MTg2ZDExNWNjYWU5OTQ3YzIvdGFibGU6NmQwZmFlM2I0NmI2NDk4OGE3MWYxMzMyODFhYjY0NTAvdGFibGVyYW5nZTo2ZDBmYWUzYjQ2YjY0OTg4YTcxZjEzMzI4MWFiNjQ1MF8yLTEtMS0xLTI3ODAz_80c9e11a-afc5-49e4-a07d-c27bade4b8fa">0001636651</ix:nonNumeric><ix:nonNumeric contextRef="i3959c496a69e480bb832a8e8833578c0_D20230505-20230505" name="dei:AmendmentFlag" format="ixt:fixed-false" id="id3VybDovL2RvY3MudjEvZG9jOjYzMTJiZTdjYmNiYTQ3NjY4YzZlZTM2N2RlOTVhMDQyL3NlYzo2MzEyYmU3Y2JjYmE0NzY2OGM2ZWUzNjdkZTk1YTA0Ml80L2ZyYWc6NzZjMThlNWFiNjY2NDk1MTg2ZDExNWNjYWU5OTQ3YzIvdGFibGU6NmQwZmFlM2I0NmI2NDk4OGE3MWYxMzMyODFhYjY0NTAvdGFibGVyYW5nZTo2ZDBmYWUzYjQ2YjY0OTg4YTcxZjEzMzI4MWFiNjQ1MF8zLTEtMS0xLTI3ODAz_99a83a5a-883a-4f52-830d-552107c78d1b">false</ix:nonNumeric></ix:hidden><ix:references xml:lang="en-US"><link:schemaRef xlink:type="simple" xlink:href="ovid-20230505.xsd"></link:schemaRef></ix:references><ix:resources><xbrli:context id="i3959c496a69e480bb832a8e8833578c0_D20230505-20230505"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001636651</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2023-05-05</xbrli:startDate><xbrli:endDate>2023-05-05</xbrli:endDate></xbrli:period></xbrli:context></ix:resources></ix:header></div><div id="i6312be7cbcba47668c6ee367de95a042_1"></div><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:4pt"><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td></tr></table></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:18pt;font-weight:700;line-height:120%">UNITED STATES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:18pt;font-weight:700;line-height:120%">SECURITIES AND EXCHANGE COMMISSION</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">WASHINGTON, D.C. 20549</span></div><div style="margin-top:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:20.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:4pt"><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td></tr></table></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:18pt;font-weight:700;line-height:120%">FORM <ix:nonNumeric contextRef="i3959c496a69e480bb832a8e8833578c0_D20230505-20230505" name="dei:DocumentType" id="id3VybDovL2RvY3MudjEvZG9jOjYzMTJiZTdjYmNiYTQ3NjY4YzZlZTM2N2RlOTVhMDQyL3NlYzo2MzEyYmU3Y2JjYmE0NzY2OGM2ZWUzNjdkZTk1YTA0Ml8xL2ZyYWc6NWMyODM0YjMzOGZiNGY0MmEwMzY2ZjRlMDc1Mzc2NDYvdGV4dHJlZ2lvbjo1YzI4MzRiMzM4ZmI0ZjQyYTAzNjZmNGUwNzUzNzY0Nl8xMjY0_53c4de14-64e7-4f3e-ae21-4a3da1a81312">8-K</ix:nonNumeric></span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:20.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:4pt"><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td></tr></table></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">CURRENT REPORT</span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934</span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Date of Report (Date of earliest event reported):</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> <ix:nonNumeric contextRef="i3959c496a69e480bb832a8e8833578c0_D20230505-20230505" name="dei:DocumentPeriodEndDate" format="ixt:date-monthname-day-year-en" id="id3VybDovL2RvY3MudjEvZG9jOjYzMTJiZTdjYmNiYTQ3NjY4YzZlZTM2N2RlOTVhMDQyL3NlYzo2MzEyYmU3Y2JjYmE0NzY2OGM2ZWUzNjdkZTk1YTA0Ml8xL2ZyYWc6NWMyODM0YjMzOGZiNGY0MmEwMzY2ZjRlMDc1Mzc2NDYvdGV4dHJlZ2lvbjo1YzI4MzRiMzM4ZmI0ZjQyYTAzNjZmNGUwNzUzNzY0Nl81NDk3NTU4MTUxNTc_d48220bf-ee4d-413f-960c-f55a15380742">May&#160;5, 2023</ix:nonNumeric></span></div><div style="margin-top:3pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:20.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:4pt"><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td></tr></table></div><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:24pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i3959c496a69e480bb832a8e8833578c0_D20230505-20230505" name="dei:EntityRegistrantName" id="id3VybDovL2RvY3MudjEvZG9jOjYzMTJiZTdjYmNiYTQ3NjY4YzZlZTM2N2RlOTVhMDQyL3NlYzo2MzEyYmU3Y2JjYmE0NzY2OGM2ZWUzNjdkZTk1YTA0Ml8xL2ZyYWc6NWMyODM0YjMzOGZiNGY0MmEwMzY2ZjRlMDc1Mzc2NDYvdGV4dHJlZ2lvbjo1YzI4MzRiMzM4ZmI0ZjQyYTAzNjZmNGUwNzUzNzY0Nl8xMjY2_322babac-0be5-4a8f-bb18-8ea73efc2b1a">OVID THERAPEUTICS INC.</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:120%"> (Exact name of Registrant as Specified in Its Charter) </span></div><div style="margin-top:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:20.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:4pt"><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.234%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:105%"><ix:nonNumeric contextRef="i3959c496a69e480bb832a8e8833578c0_D20230505-20230505" name="dei:EntityIncorporationStateCountryCode" format="ixt-sec:stateprovnameen" id="id3VybDovL2RvY3MudjEvZG9jOjYzMTJiZTdjYmNiYTQ3NjY4YzZlZTM2N2RlOTVhMDQyL3NlYzo2MzEyYmU3Y2JjYmE0NzY2OGM2ZWUzNjdkZTk1YTA0Ml8xL2ZyYWc6NWMyODM0YjMzOGZiNGY0MmEwMzY2ZjRlMDc1Mzc2NDYvdGFibGU6YWE0Yzg5ZGZlZGU2NGYzODk1YzI0N2YxNTc5NmRmMzYvdGFibGVyYW5nZTphYTRjODlkZmVkZTY0ZjM4OTVjMjQ3ZjE1Nzk2ZGYzNl8wLTAtMS0xLTI3ODAz_00f8d6ac-d88c-4e67-90e7-4d50e79dea0f">Delaware</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:105%"><ix:nonNumeric contextRef="i3959c496a69e480bb832a8e8833578c0_D20230505-20230505" name="dei:EntityFileNumber" id="id3VybDovL2RvY3MudjEvZG9jOjYzMTJiZTdjYmNiYTQ3NjY4YzZlZTM2N2RlOTVhMDQyL3NlYzo2MzEyYmU3Y2JjYmE0NzY2OGM2ZWUzNjdkZTk1YTA0Ml8xL2ZyYWc6NWMyODM0YjMzOGZiNGY0MmEwMzY2ZjRlMDc1Mzc2NDYvdGFibGU6YWE0Yzg5ZGZlZGU2NGYzODk1YzI0N2YxNTc5NmRmMzYvdGFibGVyYW5nZTphYTRjODlkZmVkZTY0ZjM4OTVjMjQ3ZjE1Nzk2ZGYzNl8wLTEtMS0xLTI3ODAz_0bac4834-be9d-4f21-b178-4d5823f659dc">001-38085</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:105%"><ix:nonNumeric contextRef="i3959c496a69e480bb832a8e8833578c0_D20230505-20230505" name="dei:EntityTaxIdentificationNumber" id="id3VybDovL2RvY3MudjEvZG9jOjYzMTJiZTdjYmNiYTQ3NjY4YzZlZTM2N2RlOTVhMDQyL3NlYzo2MzEyYmU3Y2JjYmE0NzY2OGM2ZWUzNjdkZTk1YTA0Ml8xL2ZyYWc6NWMyODM0YjMzOGZiNGY0MmEwMzY2ZjRlMDc1Mzc2NDYvdGFibGU6YWE0Yzg5ZGZlZGU2NGYzODk1YzI0N2YxNTc5NmRmMzYvdGFibGVyYW5nZTphYTRjODlkZmVkZTY0ZjM4OTVjMjQ3ZjE1Nzk2ZGYzNl8wLTItMS0xLTI3ODAz_8e930dc5-23a5-4bb9-aa88-abe9d38f77ae">46-5270895</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:105%">(State or Other Jurisdiction</span></div><div style="margin-bottom:0.75pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:105%">of Incorporation)</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:105%">(Commission File Number)</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:105%">(IRS Employer</span></div><div style="margin-bottom:0.75pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:105%">Identification No.)</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:105%"><ix:nonNumeric contextRef="i3959c496a69e480bb832a8e8833578c0_D20230505-20230505" name="dei:EntityAddressAddressLine1" id="id3VybDovL2RvY3MudjEvZG9jOjYzMTJiZTdjYmNiYTQ3NjY4YzZlZTM2N2RlOTVhMDQyL3NlYzo2MzEyYmU3Y2JjYmE0NzY2OGM2ZWUzNjdkZTk1YTA0Ml8xL2ZyYWc6NWMyODM0YjMzOGZiNGY0MmEwMzY2ZjRlMDc1Mzc2NDYvdGFibGU6YWE0Yzg5ZGZlZGU2NGYzODk1YzI0N2YxNTc5NmRmMzYvdGFibGVyYW5nZTphYTRjODlkZmVkZTY0ZjM4OTVjMjQ3ZjE1Nzk2ZGYzNl8zLTAtMS0xLTI3ODAzL3RleHRyZWdpb246NzdiZTMwN2I0ZjhkNDJhYmI3NTI3ZDQxOTYxNDgyYmVfNA_e0d16ea0-8ddc-48cb-bdda-553d9d67ce51">441 Ninth Avenue</ix:nonNumeric>, <ix:nonNumeric contextRef="i3959c496a69e480bb832a8e8833578c0_D20230505-20230505" name="dei:EntityAddressAddressLine2" id="id3VybDovL2RvY3MudjEvZG9jOjYzMTJiZTdjYmNiYTQ3NjY4YzZlZTM2N2RlOTVhMDQyL3NlYzo2MzEyYmU3Y2JjYmE0NzY2OGM2ZWUzNjdkZTk1YTA0Ml8xL2ZyYWc6NWMyODM0YjMzOGZiNGY0MmEwMzY2ZjRlMDc1Mzc2NDYvdGFibGU6YWE0Yzg5ZGZlZGU2NGYzODk1YzI0N2YxNTc5NmRmMzYvdGFibGVyYW5nZTphYTRjODlkZmVkZTY0ZjM4OTVjMjQ3ZjE1Nzk2ZGYzNl8zLTAtMS0xLTI3ODAzL3RleHRyZWdpb246NzdiZTMwN2I0ZjhkNDJhYmI3NTI3ZDQxOTYxNDgyYmVfOA_fa90cc61-1c9f-483f-af73-68b713f4c40e">14th Floor</ix:nonNumeric></span></div><div style="margin-bottom:0.75pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:105%"><ix:nonNumeric contextRef="i3959c496a69e480bb832a8e8833578c0_D20230505-20230505" name="dei:EntityAddressCityOrTown" id="id3VybDovL2RvY3MudjEvZG9jOjYzMTJiZTdjYmNiYTQ3NjY4YzZlZTM2N2RlOTVhMDQyL3NlYzo2MzEyYmU3Y2JjYmE0NzY2OGM2ZWUzNjdkZTk1YTA0Ml8xL2ZyYWc6NWMyODM0YjMzOGZiNGY0MmEwMzY2ZjRlMDc1Mzc2NDYvdGFibGU6YWE0Yzg5ZGZlZGU2NGYzODk1YzI0N2YxNTc5NmRmMzYvdGFibGVyYW5nZTphYTRjODlkZmVkZTY0ZjM4OTVjMjQ3ZjE1Nzk2ZGYzNl8zLTAtMS0xLTI3ODAzL3RleHRyZWdpb246NzdiZTMwN2I0ZjhkNDJhYmI3NTI3ZDQxOTYxNDgyYmVfMTE_ef74eb2b-0191-4035-9006-cf219e801e5c">New York</ix:nonNumeric>, <ix:nonNumeric contextRef="i3959c496a69e480bb832a8e8833578c0_D20230505-20230505" name="dei:EntityAddressStateOrProvince" format="ixt-sec:stateprovnameen" id="id3VybDovL2RvY3MudjEvZG9jOjYzMTJiZTdjYmNiYTQ3NjY4YzZlZTM2N2RlOTVhMDQyL3NlYzo2MzEyYmU3Y2JjYmE0NzY2OGM2ZWUzNjdkZTk1YTA0Ml8xL2ZyYWc6NWMyODM0YjMzOGZiNGY0MmEwMzY2ZjRlMDc1Mzc2NDYvdGFibGU6YWE0Yzg5ZGZlZGU2NGYzODk1YzI0N2YxNTc5NmRmMzYvdGFibGVyYW5nZTphYTRjODlkZmVkZTY0ZjM4OTVjMjQ3ZjE1Nzk2ZGYzNl8zLTAtMS0xLTI3ODAzL3RleHRyZWdpb246NzdiZTMwN2I0ZjhkNDJhYmI3NTI3ZDQxOTYxNDgyYmVfMTU_d9d2e7c1-3b33-4f69-87db-1d22a53ece9d">New York</ix:nonNumeric></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:105%"><ix:nonNumeric contextRef="i3959c496a69e480bb832a8e8833578c0_D20230505-20230505" name="dei:EntityAddressPostalZipCode" id="id3VybDovL2RvY3MudjEvZG9jOjYzMTJiZTdjYmNiYTQ3NjY4YzZlZTM2N2RlOTVhMDQyL3NlYzo2MzEyYmU3Y2JjYmE0NzY2OGM2ZWUzNjdkZTk1YTA0Ml8xL2ZyYWc6NWMyODM0YjMzOGZiNGY0MmEwMzY2ZjRlMDc1Mzc2NDYvdGFibGU6YWE0Yzg5ZGZlZGU2NGYzODk1YzI0N2YxNTc5NmRmMzYvdGFibGVyYW5nZTphYTRjODlkZmVkZTY0ZjM4OTVjMjQ3ZjE1Nzk2ZGYzNl8zLTItMS0xLTI3ODAzL3RleHRyZWdpb246YzYyZjMzNWUxZWNhNGEyZGFkZjFhNDgzNWNmMzgzYjhfNA_67312142-3cc5-47f1-ae4c-3858d3d16f58">10001</ix:nonNumeric></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:105%">(Address of Principal Executive Offices)</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.57pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5pt;font-weight:400;line-height:40%">&#160;&#160;</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:105%">(Zip Code)</span></td></tr></table></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Registrant&#8217;s Telephone Number, Including Area Code: <ix:nonNumeric contextRef="i3959c496a69e480bb832a8e8833578c0_D20230505-20230505" name="dei:CityAreaCode" id="id3VybDovL2RvY3MudjEvZG9jOjYzMTJiZTdjYmNiYTQ3NjY4YzZlZTM2N2RlOTVhMDQyL3NlYzo2MzEyYmU3Y2JjYmE0NzY2OGM2ZWUzNjdkZTk1YTA0Ml8xL2ZyYWc6NWMyODM0YjMzOGZiNGY0MmEwMzY2ZjRlMDc1Mzc2NDYvdGV4dHJlZ2lvbjo1YzI4MzRiMzM4ZmI0ZjQyYTAzNjZmNGUwNzUzNzY0Nl8xMjYz_2a53580e-50ec-47b1-aa19-a2d0634e7cf4">646</ix:nonNumeric>-<ix:nonNumeric contextRef="i3959c496a69e480bb832a8e8833578c0_D20230505-20230505" name="dei:LocalPhoneNumber" id="id3VybDovL2RvY3MudjEvZG9jOjYzMTJiZTdjYmNiYTQ3NjY4YzZlZTM2N2RlOTVhMDQyL3NlYzo2MzEyYmU3Y2JjYmE0NzY2OGM2ZWUzNjdkZTk1YTA0Ml8xL2ZyYWc6NWMyODM0YjMzOGZiNGY0MmEwMzY2ZjRlMDc1Mzc2NDYvdGV4dHJlZ2lvbjo1YzI4MzRiMzM4ZmI0ZjQyYTAzNjZmNGUwNzUzNzY0Nl8xMjY1_96ced9a4-d8df-46dc-94a8-d1b87aa3fcc3">661-7661</ix:nonNumeric></span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Not Applicable</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:700;line-height:120%">(Former Name or Former Address, if Changed Since Last Report)</span></div><div style="margin-top:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:20.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:4pt"><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td></tr></table></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instructions A.2. below):</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:3.596%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:94.204%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i3959c496a69e480bb832a8e8833578c0_D20230505-20230505" name="dei:WrittenCommunications" format="ixt:fixed-false" id="id3VybDovL2RvY3MudjEvZG9jOjYzMTJiZTdjYmNiYTQ3NjY4YzZlZTM2N2RlOTVhMDQyL3NlYzo2MzEyYmU3Y2JjYmE0NzY2OGM2ZWUzNjdkZTk1YTA0Ml8xL2ZyYWc6NWMyODM0YjMzOGZiNGY0MmEwMzY2ZjRlMDc1Mzc2NDYvdGFibGU6YmE0ZTJiMDEzMzhlNGY4NDlhZDJkOTU4MTVkZDQ4OTYvdGFibGVyYW5nZTpiYTRlMmIwMTMzOGU0Zjg0OWFkMmQ5NTgxNWRkNDg5Nl8wLTAtMS0xLTI3ODAz_aa8ee493-a3a5-45e4-81ce-1e919d0732d6">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</span></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i3959c496a69e480bb832a8e8833578c0_D20230505-20230505" name="dei:SolicitingMaterial" format="ixt:fixed-false" id="id3VybDovL2RvY3MudjEvZG9jOjYzMTJiZTdjYmNiYTQ3NjY4YzZlZTM2N2RlOTVhMDQyL3NlYzo2MzEyYmU3Y2JjYmE0NzY2OGM2ZWUzNjdkZTk1YTA0Ml8xL2ZyYWc6NWMyODM0YjMzOGZiNGY0MmEwMzY2ZjRlMDc1Mzc2NDYvdGFibGU6YmE0ZTJiMDEzMzhlNGY4NDlhZDJkOTU4MTVkZDQ4OTYvdGFibGVyYW5nZTpiYTRlMmIwMTMzOGU0Zjg0OWFkMmQ5NTgxNWRkNDg5Nl8yLTAtMS0xLTI3ODAz_43ec5151-5468-4db3-a8a2-b31689957a5c">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) </span></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i3959c496a69e480bb832a8e8833578c0_D20230505-20230505" name="dei:PreCommencementTenderOffer" format="ixt:fixed-false" id="id3VybDovL2RvY3MudjEvZG9jOjYzMTJiZTdjYmNiYTQ3NjY4YzZlZTM2N2RlOTVhMDQyL3NlYzo2MzEyYmU3Y2JjYmE0NzY2OGM2ZWUzNjdkZTk1YTA0Ml8xL2ZyYWc6NWMyODM0YjMzOGZiNGY0MmEwMzY2ZjRlMDc1Mzc2NDYvdGFibGU6YmE0ZTJiMDEzMzhlNGY4NDlhZDJkOTU4MTVkZDQ4OTYvdGFibGVyYW5nZTpiYTRlMmIwMTMzOGU0Zjg0OWFkMmQ5NTgxNWRkNDg5Nl80LTAtMS0xLTI3ODAz_f311148b-32bb-40bd-9ee2-f2330e4bf609">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) </span></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i3959c496a69e480bb832a8e8833578c0_D20230505-20230505" name="dei:PreCommencementIssuerTenderOffer" format="ixt:fixed-false" id="id3VybDovL2RvY3MudjEvZG9jOjYzMTJiZTdjYmNiYTQ3NjY4YzZlZTM2N2RlOTVhMDQyL3NlYzo2MzEyYmU3Y2JjYmE0NzY2OGM2ZWUzNjdkZTk1YTA0Ml8xL2ZyYWc6NWMyODM0YjMzOGZiNGY0MmEwMzY2ZjRlMDc1Mzc2NDYvdGFibGU6YmE0ZTJiMDEzMzhlNGY4NDlhZDJkOTU4MTVkZDQ4OTYvdGFibGVyYW5nZTpiYTRlMmIwMTMzOGU0Zjg0OWFkMmQ5NTgxNWRkNDg5Nl82LTAtMS0xLTI3ODAz_054196f3-52c9-4b1f-a4c8-a7bb11bcd8df">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</span></td></tr></table></div><div style="margin-top:1pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Securities registered pursuant to Section 12(b) of the Act:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.848%"><tr><td style="width:1.0%"></td><td style="width:38.505%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.558%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.171%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.558%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:38.508%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:105%">Title of each class</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:105%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:105%">Trading</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:105%">Symbol(s)</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:105%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:105%">Name of each exchange on which registered</span></td></tr><tr><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%"><ix:nonNumeric contextRef="i3959c496a69e480bb832a8e8833578c0_D20230505-20230505" name="dei:Security12bTitle" id="id3VybDovL2RvY3MudjEvZG9jOjYzMTJiZTdjYmNiYTQ3NjY4YzZlZTM2N2RlOTVhMDQyL3NlYzo2MzEyYmU3Y2JjYmE0NzY2OGM2ZWUzNjdkZTk1YTA0Ml8xL2ZyYWc6NWMyODM0YjMzOGZiNGY0MmEwMzY2ZjRlMDc1Mzc2NDYvdGFibGU6MzMzMWIwNzJjNGVmNDBmODk0NzlkNWI2NmY5NDVmYmYvdGFibGVyYW5nZTozMzMxYjA3MmM0ZWY0MGY4OTQ3OWQ1YjY2Zjk0NWZiZl8xLTAtMS0xLTI3ODAz_58b0c82e-9db7-4cc7-8663-6bc46381a9bc">Common Stock, par value $0.001 per share</ix:nonNumeric> </span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%">&#160;</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%"><ix:nonNumeric contextRef="i3959c496a69e480bb832a8e8833578c0_D20230505-20230505" name="dei:TradingSymbol" id="id3VybDovL2RvY3MudjEvZG9jOjYzMTJiZTdjYmNiYTQ3NjY4YzZlZTM2N2RlOTVhMDQyL3NlYzo2MzEyYmU3Y2JjYmE0NzY2OGM2ZWUzNjdkZTk1YTA0Ml8xL2ZyYWc6NWMyODM0YjMzOGZiNGY0MmEwMzY2ZjRlMDc1Mzc2NDYvdGFibGU6MzMzMWIwNzJjNGVmNDBmODk0NzlkNWI2NmY5NDVmYmYvdGFibGVyYW5nZTozMzMxYjA3MmM0ZWY0MGY4OTQ3OWQ1YjY2Zjk0NWZiZl8xLTItMS0xLTI3ODAz_a256b228-71bf-4853-9e68-b8a2430b4474">OVID</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%">&#160;</span></td><td colspan="3" style="border-top:0.5pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%"><ix:nonNumeric contextRef="i3959c496a69e480bb832a8e8833578c0_D20230505-20230505" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" id="id3VybDovL2RvY3MudjEvZG9jOjYzMTJiZTdjYmNiYTQ3NjY4YzZlZTM2N2RlOTVhMDQyL3NlYzo2MzEyYmU3Y2JjYmE0NzY2OGM2ZWUzNjdkZTk1YTA0Ml8xL2ZyYWc6NWMyODM0YjMzOGZiNGY0MmEwMzY2ZjRlMDc1Mzc2NDYvdGFibGU6MzMzMWIwNzJjNGVmNDBmODk0NzlkNWI2NmY5NDVmYmYvdGFibGVyYW5nZTozMzMxYjA3MmM0ZWY0MGY4OTQ3OWQ1YjY2Zjk0NWZiZl8xLTQtMS0xLTI3ODAz_5f24d9ac-a100-49c9-8373-88574baf2207">The Nasdaq Stock Market LLC</ix:nonNumeric></span></td></tr></table></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:4pt"><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"></td></tr></table></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (&#167;&#8201;230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (&#167;&#8201;240.12b-2 of this chapter).</span></div><div style="margin-top:6pt;text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Emerging growth company <ix:nonNumeric contextRef="i3959c496a69e480bb832a8e8833578c0_D20230505-20230505" name="dei:EntityEmergingGrowthCompany" format="ixt:fixed-false" id="id3VybDovL2RvY3MudjEvZG9jOjYzMTJiZTdjYmNiYTQ3NjY4YzZlZTM2N2RlOTVhMDQyL3NlYzo2MzEyYmU3Y2JjYmE0NzY2OGM2ZWUzNjdkZTk1YTA0Ml8xL2ZyYWc6NWMyODM0YjMzOGZiNGY0MmEwMzY2ZjRlMDc1Mzc2NDYvdGV4dHJlZ2lvbjo1YzI4MzRiMzM4ZmI0ZjQyYTAzNjZmNGUwNzUzNzY0Nl8xMjU2_03a8d9e4-5f08-4670-86b1-bde8d70c5d12">&#9744;</ix:nonNumeric> </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.&#9744; </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><div id="i6312be7cbcba47668c6ee367de95a042_7"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:12pt;margin-top:12pt;padding-left:72pt;text-indent:-72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 2.02.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:29.52pt">Results of Operations and Financial Condition.</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On May&#160;5, 2023, Ovid Therapeutics Inc. (the &#8220;Company&#8221;) issued a press release announcing First Quarter 2023 Financial Results and Corporate Updates. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-indent:27.74pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The information provided in this Item 2.02, including Exhibit 99.1 hereto, shall not be deemed &#8220;filed&#8221; for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing.</span></div><div id="i6312be7cbcba47668c6ee367de95a042_10"></div><div style="-sec-extract:summary;margin-bottom:12pt;margin-top:12pt;padding-left:72pt;text-indent:-72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 9.01.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:29.52pt">Financial Statements and Exhibits.</span></div><div style="margin-bottom:12pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(d) Exhibit</span></div><div style="margin-bottom:12pt;margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:19.960%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.557%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:77.083%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:105%">Exhibit No.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:105%">Description</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:105%">&#160;&#160;</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%">99.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%;text-decoration:underline" href="ovid2023q1exhibit991.htm">Press Release, dated</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%;text-decoration:underline"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%">May&#160;5, 2023</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%">104</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%">Cover Page Interactive Data File (embedded within the Inline XBRL document)</span></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><div id="i6312be7cbcba47668c6ee367de95a042_13"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SIGNATURES</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-indent:26.19pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</span></div><div style="margin-bottom:12pt;margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:54.506%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.203%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:37.991%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:105%">OVID THERAPEUTICS INC.</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%">&#160;&#160;</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%">&#160;&#160;</span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%">By: </span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%">&#160;/s/ Thomas M. Perone</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:105%">&#160;&#160;</span></div></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%">Thomas M. Perone</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:105%">&#160;&#160;</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%">General Counsel &amp; Corporate Secretary </span></td></tr></table></div><div style="margin-bottom:12pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Dated: <ix:nonNumeric contextRef="i3959c496a69e480bb832a8e8833578c0_D20230505-20230505" name="dei:DocumentPeriodEndDate" format="ixt:date-monthname-day-year-en" id="id3VybDovL2RvY3MudjEvZG9jOjYzMTJiZTdjYmNiYTQ3NjY4YzZlZTM2N2RlOTVhMDQyL3NlYzo2MzEyYmU3Y2JjYmE0NzY2OGM2ZWUzNjdkZTk1YTA0Ml8xMy9mcmFnOjY0MDYxZTQzYjhjNDQzZmJiNjQ5YTBjYWQ4MGYwODQ0L3RleHRyZWdpb246NjQwNjFlNDNiOGM0NDNmYmI2NDlhMGNhZDgwZjA4NDRfNTQ5NzU1ODE0MTAw_d48220bf-ee4d-413f-960c-f55a15380742">May&#160;5, 2023</ix:nonNumeric></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>ovid2023q1exhibit991.htm
<DESCRIPTION>EX-99.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2023 Workiva -->
<title>Document</title></head><body><div id="id728bf9627774dab96c5661fca4ca0b8_1"></div><div style="min-height:45pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Exhibit 99.1</font></div><div style="text-align:center"><img alt="img34400995_0a.jpg" src="img34400995_0a.jpg" style="height:70px;margin-bottom:5pt;vertical-align:text-bottom;width:220px"></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:14pt;font-weight:700;line-height:120%">Ovid Therapeutics Reports First Quarter 2023 Financial Results and </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:14pt;font-weight:700;line-height:120%">Corporate Updates</font></div><div style="padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:107%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:107%;padding-left:13.8pt">Initiated collaboration with Graviton Bioscience to develop selective ROCK2 inhibitors for rare neurological diseases</font></div><div><font><br></font></div><div style="padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:107%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:107%;padding-left:13.8pt">Long-term data supporting soticlestat safety, tolerability and seizure-reduction efficacy presented by Takeda at the American Academy of Neurology meeting</font></div><div><font><br></font></div><div style="padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:107%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:107%;padding-left:14.15pt">OV329 Phase 1 trial continues to progress on track with no safety signals </font></div><div><font><br></font></div><div style="padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:107%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:107%;padding-left:13.8pt">Company to prioritize development of its clinical small molecule programs&#59; intends to conclude and explore the out-licensing of its genetic medicine programs with Columbia University </font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:112%">NEW YORK, May&#160;5, 2023</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:112%">--</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%"> Ovid Therapeutics Inc. (NASDAQ&#58; OVID), a biopharmaceutical company committed to developing medicines that transform the lives of people with rare epilepsies and seizure-related disorders, today reported business updates and financial results for the first quarter ended March&#160;31, 2023.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#8220;Our recent transaction with Graviton adds a clinical stage program with a novel mechanism of action to our pipeline of potential first-in-class or potential best-in-class medicines for rare epilepsies and seizure-related disorders. We are excited to explore the therapeutic opportunity of applying ROCK2 inhibition for people suffering with serious neurological conditions, beginning with brainstem cavernous malformations, a grave condition that has no approved medicine today,&#8221; said Jeremy Levin, D.Phil, MB BChir, Ovid's Chairman and CEO.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:107%">&#8220;Importantly, all elements of our pipeline are progressing. We are encouraged by long-term and post hoc analyses on soticlestat, recently presented by Takeda, and look forward to seeing results from the Phase 3 pivotal trials. Additionally, we have assembled a unique set of programs, anchored by four potential best-in-class or only-in-class mechanisms of action, including&#58; selective ROCK2 inhibition, GABA-aminotransferase inhibition, direct KCC2 activation and cholesterol 24-hydroxylase inhibition that was since out-licensed to Takeda, The mechanisms in this pipeline strategically position Ovid to be a leader in rare seizure-related disorders. Collectively, we believe these programs will deliver multiple clinical milestones that can generate value for patients and shareholders,&#8221; added Dr. Levin.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:107%">First Quarter Business Update</font></div><div><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:112%;padding-left:13.8pt">R&#38;D strategy</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#58; Ovid is prioritizing its pipeline of small molecule programs, to which it recently added GV101 and a library of novel ROCK2 inhibitor compounds through its collaboration with Graviton Bioscience (Graviton). The Company&#8217;s efforts focus on establishing therapeutic proof-of-concept in humans using efficient, signal-finding trials and validated biomarkers of efficacy. Ovid will conclude its research collaboration with Columbia University by year-end 2023 and explore business development opportunities for its non-core genetic programs produced from that research initiative.  </font></div><div style="text-align:justify"><font><br></font></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:45pt;width:100%"><div><font><br></font></div></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:107%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:107%;padding-left:13.8pt">Financial strategy</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:107%">&#58; Ovid anticipates its cash runway should fund operations into 2025 without additional funding. Ovid plans to direct capital to clinical opportunities that it believes to be value-creating for shareholders. To support this strategy, Ovid instituted cost-cutting measures that began in 2022 and continue into this year, such as the conclusion of its genetic programs with Columbia University and other administrative cost saving activities. Apart from its current runway projections, Ovid is eligible to receive additional non-dilutive capital from Takeda, if and when soticlestat is successfully approved and marketed. Takeda has guided that it anticipates filing for global regulatory approvals of soticlestat in its fiscal year 2024.</font></div><div><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:107%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:107%;padding-left:14.15pt">Business development activities</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:107%">&#58; The Company's recent collaboration with Graviton adds a clinical stage program and preclinical assets to Ovid's pipeline, achieving one of Ovid's annual goals. Future business development efforts will focus on exploring out-licensing opportunities for Ovid's genetic programs, as well as potential partnerships to advance development opportunities for its assets in indications outside of seizures. </font></div><div style="text-align:justify"><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:107%">The Company intends to make disciplined strategic investments in its scientific and leadership team to steward the business and its programs.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:107%">Pipeline Update</font></div><div><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:112%;padding-left:13.8pt">GV101 and selective ROCK2 inhibitor library&#58;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%"> In May 2023, Ovid entered into a collaboration agreement with Graviton and is initiating clinical development work to support a pivotal formulation and dose for its lead asset, GV101. Ovid seeks to take GV101 into a potential Phase 2 trial for the treatment of cavernous malformations located in the brainstem in 2024. GV101 is a potent, highly selective ROCK2 inhibitor that has previously been shown to be blood-brain barrier penetrant in animals. Additionally, GV101 was generally well tolerated in a prior Phase 1 study in healthy volunteers using a nano-suspension formulation. Working through a joint development committee with Graviton, Ovid intends to initiate a multiple ascending dose study in the second half of 2023 to confirm its preferred dose in a gel capsule formulation. In parallel, Graviton is working to open a potential IND application in cavernous malformations of the brain. </font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:107%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:107%;padding-left:13.8pt">OV329, a potential next generation GABA-aminotransferase (GABA-AT) inhibitor, is on track in a Phase 1 trial of healthy volunteers.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:107%"> The Company has seen no safety signals in single ascending dose cohorts conducted to date. Ovid believes OV329 is more potent than prior GABA-AT inhibitors, and therefore may provide significant seizure reduction efficacy, an improved safety profile, and preferable (lower) dosing. Ovid anticipates full Phase 1 findings in the first half of 2024, including biomarker data that may serve as a proxy for seizure reduction efficacy. Additional long-term animal toxicology programs and efficacy models are ongoing to further support development and future indication selection. </font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:107%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:107%;padding-left:13.8pt">OV350, the lead compound in Ovid's KCC2 portfolio, is advancing in preclinical studies. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:107%">The objective of current studies is to support future clinical development in seizure-related disorders. In addition to OV350, Ovid is characterizing other compounds in the unique KCC2 activator library to identify oral formulations and to explore the potential relevance of the KCC2 transporter target in animal models of additional diseases. </font></div><div><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:112%;padding-left:13.8pt">Soticlestat is progressing in two Phase 3 pivotal trials for Lennox-Gastaut syndrome (LGS) and Dravet syndrome (DS). Takeda recently presented a positive analysis of long-term data on patients taking soticlestat at the 2023 American Academy of Neurology meeting</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">. An analysis of patients who participated in a long-term open label extension study called ENDYMION 1 showed that at two years of treatment with soticlestat, the compound was generally safe and well tolerated, consistent with prior studies. Additionally, it showed </font></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:45pt;width:100%"><div><font><br></font></div></div><div style="padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">sustained reduction in frequency of drop seizures among LGS patients and convulsive seizures among DS patients as well as sustained reductions in the frequency of all-seizures from baseline for up to two years across both cohorts. A separate analysis of the Phase 2 study, ELEKTRA, was presented and found a reduction in median seizure frequency across multiple seizure types. Ovid is eligible to receive regulatory and commercial milestone payments of up to $660 million, as well as royalties of up to 20% on global sales, if regulatory approval is received and soticlestat is commercialized.</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:112%;padding-left:13.8pt">Concluding genetic research collaboration with Columbia University</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">. By year-end 2023, Ovid will conclude its three-year research collaboration with Columbia to focus its capabilities on the development of its small molecules and seizure-related disorder candidates. The portfolio includes OV815, OV825, and OV835, which are novel and viable preclinical candidates and programs. The Company will explore business development opportunities to maximize the scientific and therapeutic potential of these programs and return on investment. </font></div><div id="id728bf9627774dab96c5661fca4ca0b8_7"></div><div style="margin-bottom:10pt;margin-top:10pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:107%">First Quarter 2023 Financial Results</font></div><div style="margin-bottom:10pt;margin-top:10pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:13.8pt">Cash, cash equivalents and marketable securities as of March&#160;31, 2023, totaled $117.7 million.</font></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%;padding-left:13.8pt">Revenue was $66,160 for the three months ended March&#160;31, 2023, and $1.4 million for the same period in 2022. Revenue in the three months ended March 31, 2023, was from ZTALMY&#174; (ganaxolone) royalties from Marinus Pharmaceuticals, Inc., and revenue for the same period in 2022 was generated from licensing and other agreements.</font></div><div style="margin-bottom:10pt;margin-top:10pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:13.8pt">Research and development expenses were $6.6 million for the three months ended March&#160;31, 2023, as compared to $7.8 million for the same period in 2022. The decrease was due to cessation of clinical development programs related to gaboxadol and soticlestat, offset by clinical development costs for OV329.</font></div><div style="margin-bottom:10pt;margin-top:10pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:14.5pt">General and administrative expenses were $8.3 million for the three months ended March&#160;31, 2023, as compared to $9.9 million for the same period in 2022. The decrease was due to personnel cost reductions following corporate cost-cutting efforts and a headcount reduction conducted in March 2022.</font></div><div style="margin-bottom:10pt;margin-top:10pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:14.5pt">Total operating expenses were $15.0 million in the three months ended March&#160;31, 2023, as compared to $17.7 million for the same period last year. The decrease was a result of the above mentioned expense reduction efforts undertaken in 2022.</font></div><div style="margin-bottom:10pt;margin-top:10pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:14.5pt">Ovid reported a net loss of $13.4 million, or basic and diluted net loss per share attributable to common stockholders of $0.19, for the three months ended March&#160;31, 2023, as compared to a net loss of $16.1 million, or basic and diluted net loss per share attributable to common stockholders of $0.23, for the same period in 2022.</font></div><div id="id728bf9627774dab96c5661fca4ca0b8_13"></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">About Ovid Therapeutics</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">Ovid Therapeutics Inc. is a New York-based biopharmaceutical company striving to conquer seizures and brain disorders with courageous science. Ovid&#8217;s pipeline of small molecule candidates seek to meaningfully improve the lives of people and families affected by rare epilepsies and seizure-related disorders. Ovid seeks to develop&#58; GV101, a potent and highly selective ROCK2 inhibitor for the potential treatment of lesions associated with cavernous cerebral malformations&#59; OV329, a GABA-aminotransferase inhibitor, for treatment-resistant seizures, and OV350, a direct activator of the KCC2 transporter, for potential treatment of epilepsies. In addition, Ovid maintains a significant financial interest in the future regulatory development and potential commercialization of soticlestat, which </font></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:45pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">Takeda is responsible for advancing globally. Soticlestat is a cholesterol 24-hydroxylase inhibitor, which is currently in Phase 3 trials for Dravet and Lennox-Gastaut syndromes. For more information about these and other Ovid research programs, please visit www.ovidrx.com.</font></div><div id="id728bf9627774dab96c5661fca4ca0b8_16"></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Forward-Looking Statements</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">This press release includes certain disclosures that contain &#8220;forward-looking statements,&#8221; including, without limitation&#58; statements regarding the Phase 1 study in healthy volunteers for OV329&#59; the potential use of OV329, GV101 and OV350&#59; the clinical and regulatory development of our programs, including the anticipated timing of clinical data&#59; the likelihood that data for OV329, GV101 and OV350 will support future development and therapeutic potential&#59; the potential development of GV101 and the library of ROCK2 inhibitors and OV350 and other KCC2 compounds in Ovid&#8217;s library&#59; the suitability of Ovid&#8217;s library of novel, direct KCC2 transporter activators and the library of ROCK2 inhibitors for a range of formulations and administrations&#59; the timing for filing of Ovid&#8217;s IND applications&#59; the potential development and therapeutic opportunity of GV101 and other Rho&#47;Rho associated coiled-coil containing protein kinase 2 inhibitors&#59; and the potential safety, selectivity and potency of GV101 and other ROCK2 inhibitors&#59; the timing for the completion of Takeda&#8217;s two pivotal Phase 3 trials evaluating soticlestat for Dravet syndrome and Lennox-Gastaut syndrome&#59; and the duration of Ovid&#8217;s expectations regarding its cash runway and the expectation that it will support the advancement of Ovid&#8217;s pipeline. You can identify forward-looking statements because they contain words such as &#8220;anticipates,&#8221; &#8220;believes,&#8221; &#8220;expected,&#8221; &#8220;intends,&#8221; &#34;may,&#34; &#8220;plan,&#8221; &#8220;potentially,&#8221; &#8220;seek,&#8221; &#8220;strive&#8221; and &#8220;will,&#8221; and similar expressions (as well as other words or expressions referencing future events, conditions or circumstances). Forward-looking statements are based on Ovid&#8217;s current expectations and assumptions. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that may differ materially from those contemplated by the forward-looking statements, which are neither statements of historical fact nor guarantees or assurances of future performance. Important factors that could cause actual results to differ materially from those in the forward-looking statements include, without limitation, uncertainties inherent in the preclinical and clinical development and regulatory approval processes, risks related to Ovid&#8217;s ability to achieve its financial objectives, the risk that Ovid may not be able to realize the intended benefits of its technology or its business strategy, or risks related to Ovid&#8217;s ability to identify business development targets or strategic partners, to enter into strategic transactions on favorable terms, or to consummate and realize the benefits of any business development transactions. Additional risks that could cause actual results to differ materially from those in the forward-looking statements are set forth under the caption &#8220;Risk Factors&#8221; in Ovid&#8217;s Annual Report on Form 10-K filed with the Securities and Exchange Commission (&#8220;SEC&#8221;) on March 13, 2023, and in future filings Ovid makes with the SEC. Any forward-looking statements contained in this press release speak only as of the date hereof, and Ovid assumes no obligation to update any forward-looking statements contained herein, whether because of any new information, future events, changed circumstances or otherwise, except as otherwise required by law.</font></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><div id="id728bf9627774dab96c5661fca4ca0b8_22"></div><hr style="page-break-after:always"><div style="min-height:45pt;width:100%"><div><font><br></font></div></div><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Condensed Consolidated Statements of Operations</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Unaudited</font></div><div style="margin-bottom:12pt;margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.393%"><tr><td style="width:1.0%"></td><td style="width:69.174%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.381%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.562%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.383%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Three Months Ended March 31, 2023</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the Three Months Ended March 31, 2022</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenue&#58;</font></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">License and other revenue</font></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">66,160&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,445,366&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">License revenue - related party</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total revenue</font></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">66,160&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,445,366&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating expenses&#58;</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,614,717&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,832,269&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,343,748&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,880,203&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total operating expenses</font></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,958,465&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,712,472&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss from operations</font></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(14,892,304)</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(16,267,106)</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other income (expense), net</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,536,095&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">159,050&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss before provision for income taxes</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(13,356,209)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(16,108,056)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Provision for income taxes</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(13,356,209)</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(16,108,056)</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss per share, basic</font></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.19)</font></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.23)</font></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss per share, diluted</font></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.19)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.23)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average common shares outstanding, basic</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">70,490,704&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">70,345,828&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average common shares outstanding, diluted</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">70,490,704&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">70,345,828&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div id="id728bf9627774dab96c5661fca4ca0b8_25"></div><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Select Condensed Balance Sheet Data</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Unaudited</font></div><div style="margin-bottom:12pt;margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:49.960%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:22.990%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.557%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:22.993%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#bf2115;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:105%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31, 2023</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2022</font></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%">Cash, cash equivalents and marketable securities</font></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">117,720,021&#160;</font></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">129,001,411&#160;</font></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%">Working capital</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:105%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</font></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">112,798,366&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">124,389,166&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%">Total assets</font></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">143,367,004&#160;</font></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">155,265,814&#160;</font></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%">Total stockholder's equity</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">120,947,682&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">132,272,564&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="12" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:105%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%">Working capital defined as current assets less current liabilities</font></div></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><div id="id728bf9627774dab96c5661fca4ca0b8_28"></div><hr style="page-break-after:always"><div style="min-height:45pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Contacts</font></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Investors and Media&#58;</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Ovid Therapeutics Inc.</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Meg Alexander</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Chief Corporate Affairs Officer</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">917-943-6681</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">malexander&#64;ovidrx.com </font></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">OR</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Investors</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#58;</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Argot Partners</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Maeve Conneighton</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">212-596-7231</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">ovid&#64;argotpartners.com </font></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>3
<FILENAME>ovid-20230505.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2023 Workiva-->
<!--r:49487af2-aa3d-46a1-bf94-ce7758f1a580,g:6ad0f39e-08b7-480f-9056-de0fc16a9d03-->
<xs:schema xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:ovid="http://www.ovidrx.com/20230505" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://www.ovidrx.com/20230505">
  <xs:import namespace="http://www.w3.org/1999/xlink" schemaLocation="http://www.xbrl.org/2003/xlink-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/dei/2022" schemaLocation="https://xbrl.sec.gov/dei/2022/dei-2022.xsd"/>
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="ovid-20230505_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="ovid-20230505_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="ovid-20230505_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:type="simple"/>
      <link:roleType id="Cover" roleURI="http://www.ovidrx.com/role/Cover">
        <link:definition>0000001 - Document - Cover</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>4
<FILENAME>ovid-20230505_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2023 Workiva-->
<!--r:49487af2-aa3d-46a1-bf94-ce7758f1a580,g:6ad0f39e-08b7-480f-9056-de0fc16a9d03-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member"/>
  <link:roleRef roleURI="http://www.ovidrx.com/role/Cover" xlink:type="simple" xlink:href="ovid-20230505.xsd#Cover"/>
  <link:definitionLink xlink:role="http://www.ovidrx.com/role/Cover" xlink:type="extended" id="if3a99b905d444e3b9029becc945fd9a2_Cover">
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentInformationLineItems_ca27e1be-9d32-4594-8664-4d24308f73e0" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentInformationLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_54f83273-8ca6-4c64-a892-a0b7b741e9d5" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_ca27e1be-9d32-4594-8664-4d24308f73e0" xlink:to="loc_dei_DocumentPeriodEndDate_54f83273-8ca6-4c64-a892-a0b7b741e9d5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentInformationTable_1a102a0e-cdac-425c-b3f5-bd979b9d3920" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentInformationTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_dei_DocumentInformationLineItems_ca27e1be-9d32-4594-8664-4d24308f73e0" xlink:to="loc_dei_DocumentInformationTable_1a102a0e-cdac-425c-b3f5-bd979b9d3920" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
  </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>5
<FILENAME>ovid-20230505_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2023 Workiva-->
<!--r:49487af2-aa3d-46a1-bf94-ce7758f1a580,g:6ad0f39e-08b7-480f-9056-de0fc16a9d03-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel"/>
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:label id="lab_dei_EntityCentralIndexKey_f2e8822b-7fd5-4e6b-8b39-8aed7f4f21fa_terseLabel_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:label id="lab_dei_EntityCentralIndexKey_label_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey" xlink:to="lab_dei_EntityCentralIndexKey" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine2_6fc29c7f-282c-4432-990f-a025b256ba43_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line Two</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine2_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine2" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine2"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine2" xlink:to="lab_dei_EntityAddressAddressLine2" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine1_431cfece-0a25-4833-99d6-fbadd6bb4da4_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine1_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine1" xlink:to="lab_dei_EntityAddressAddressLine1" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_TradingSymbol_c183f4ef-4706-475a-a17b-16fa1a30abec_terseLabel_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:label id="lab_dei_TradingSymbol_label_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol" xlink:to="lab_dei_TradingSymbol" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFileNumber_a34a2a3a-241d-43a2-91c2-fd8c48f01ba3_terseLabel_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:label id="lab_dei_EntityFileNumber_label_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFileNumber" xlink:to="lab_dei_EntityFileNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SolicitingMaterial_37f3f204-592b-4216-a504-222b2bb9846f_terseLabel_en-US" xlink:label="lab_dei_SolicitingMaterial" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Soliciting Material</link:label>
    <link:label id="lab_dei_SolicitingMaterial_label_en-US" xlink:label="lab_dei_SolicitingMaterial" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Soliciting Material</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SolicitingMaterial" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SolicitingMaterial"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SolicitingMaterial" xlink:to="lab_dei_SolicitingMaterial" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_b1c9deb7-abb1-4b3b-b225-44ad91dc5927_terseLabel_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_label_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityIncorporationStateCountryCode" xlink:to="lab_dei_EntityIncorporationStateCountryCode" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressPostalZipCode_35958a79-407d-4a5d-b8fb-b96c525d1570_terseLabel_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:label id="lab_dei_EntityAddressPostalZipCode_label_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressPostalZipCode" xlink:to="lab_dei_EntityAddressPostalZipCode" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentInformationLineItems_d8defc79-ec11-4cea-a397-396079bb353e_terseLabel_en-US" xlink:label="lab_dei_DocumentInformationLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Information [Line Items]</link:label>
    <link:label id="lab_dei_DocumentInformationLineItems_label_en-US" xlink:label="lab_dei_DocumentInformationLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Information [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentInformationLineItems" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentInformationLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentInformationLineItems" xlink:to="lab_dei_DocumentInformationLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CityAreaCode_0f423fc6-387d-44b9-af3f-80a9063db602_terseLabel_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:label id="lab_dei_CityAreaCode_label_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CityAreaCode" xlink:to="lab_dei_CityAreaCode" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_Security12bTitle_3e627c34-9696-493c-a8a2-99df6f77f2fc_terseLabel_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:label id="lab_dei_Security12bTitle_label_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_Security12bTitle" xlink:to="lab_dei_Security12bTitle" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AmendmentFlag_eec9c3e1-2f8d-40e1-bf56-8dc21b6b9f77_terseLabel_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:label id="lab_dei_AmendmentFlag_label_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag" xlink:to="lab_dei_AmendmentFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SecurityExchangeName_1d97b93e-65fc-49b9-a2a0-9f5c5bbac204_terseLabel_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:label id="lab_dei_SecurityExchangeName_label_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityExchangeName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SecurityExchangeName" xlink:to="lab_dei_SecurityExchangeName" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityRegistrantName_4c68dd30-f6d0-4b87-aa7c-df8677242953_terseLabel_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:label id="lab_dei_EntityRegistrantName_label_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName" xlink:to="lab_dei_EntityRegistrantName" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentPeriodEndDate_78c050d0-50b6-4bb7-9be9-7ae32a410255_terseLabel_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:label id="lab_dei_DocumentPeriodEndDate_label_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate" xlink:to="lab_dei_DocumentPeriodEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_2e6bc260-7277-4c29-a695-dacb28a205dd_terseLabel_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_label_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityTaxIdentificationNumber" xlink:to="lab_dei_EntityTaxIdentificationNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_PreCommencementIssuerTenderOffer_cc509218-2693-4a31-a28c-29f83ab5a58c_terseLabel_en-US" xlink:label="lab_dei_PreCommencementIssuerTenderOffer" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
    <link:label id="lab_dei_PreCommencementIssuerTenderOffer_label_en-US" xlink:label="lab_dei_PreCommencementIssuerTenderOffer" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementIssuerTenderOffer" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_PreCommencementIssuerTenderOffer"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_PreCommencementIssuerTenderOffer" xlink:to="lab_dei_PreCommencementIssuerTenderOffer" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressCityOrTown_27817b99-ebb4-49b3-9c9b-819840421efa_terseLabel_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:label id="lab_dei_EntityAddressCityOrTown_label_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCityOrTown" xlink:to="lab_dei_EntityAddressCityOrTown" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LocalPhoneNumber_f68c4395-82ab-42fb-a51b-20b55f113fd2_terseLabel_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:label id="lab_dei_LocalPhoneNumber_label_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LocalPhoneNumber" xlink:to="lab_dei_LocalPhoneNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_WrittenCommunications_cf52c3bc-06a3-43d4-a967-691e94b4a339_terseLabel_en-US" xlink:label="lab_dei_WrittenCommunications" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Written Communications</link:label>
    <link:label id="lab_dei_WrittenCommunications_label_en-US" xlink:label="lab_dei_WrittenCommunications" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Written Communications</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_WrittenCommunications" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_WrittenCommunications"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_WrittenCommunications" xlink:to="lab_dei_WrittenCommunications" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CoverAbstract_label_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CoverAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CoverAbstract" xlink:to="lab_dei_CoverAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentType_46abb0c7-0151-4ff3-bf4e-fee1d759618d_terseLabel_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:label id="lab_dei_DocumentType_label_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType" xlink:to="lab_dei_DocumentType" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentInformationTable_393fb2a3-4e61-4d4b-aad5-a58dd87efded_terseLabel_en-US" xlink:label="lab_dei_DocumentInformationTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Information [Table]</link:label>
    <link:label id="lab_dei_DocumentInformationTable_label_en-US" xlink:label="lab_dei_DocumentInformationTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Information [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentInformationTable" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentInformationTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentInformationTable" xlink:to="lab_dei_DocumentInformationTable" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_701afbd2-ac0f-44fa-86f8-ee05c2f8f94f_terseLabel_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_label_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany" xlink:to="lab_dei_EntityEmergingGrowthCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressStateOrProvince_66df221c-d49a-4fe2-92fc-89c5cf6d1773_terseLabel_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:label id="lab_dei_EntityAddressStateOrProvince_label_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressStateOrProvince"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressStateOrProvince" xlink:to="lab_dei_EntityAddressStateOrProvince" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_PreCommencementTenderOffer_9258dd2e-1048-4fbf-8cdb-3dbd6db8b864_terseLabel_en-US" xlink:label="lab_dei_PreCommencementTenderOffer" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
    <link:label id="lab_dei_PreCommencementTenderOffer_label_en-US" xlink:label="lab_dei_PreCommencementTenderOffer" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementTenderOffer" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_PreCommencementTenderOffer"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_PreCommencementTenderOffer" xlink:to="lab_dei_PreCommencementTenderOffer" xlink:type="arc" order="1"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>6
<FILENAME>ovid-20230505_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2023 Workiva-->
<!--r:49487af2-aa3d-46a1-bf94-ce7758f1a580,g:6ad0f39e-08b7-480f-9056-de0fc16a9d03-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.ovidrx.com/role/Cover" xlink:type="simple" xlink:href="ovid-20230505.xsd#Cover"/>
  <link:presentationLink xlink:role="http://www.ovidrx.com/role/Cover" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract_19663ab4-a456-4595-9ef0-a80af45873a1" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_843ea5c7-0c13-488b-8cdf-b2d1f1d5daf8" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_19663ab4-a456-4595-9ef0-a80af45873a1" xlink:to="loc_dei_DocumentType_843ea5c7-0c13-488b-8cdf-b2d1f1d5daf8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_cc6cbb3e-d1b5-4b76-877a-4bfab28ed31a" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_19663ab4-a456-4595-9ef0-a80af45873a1" xlink:to="loc_dei_DocumentPeriodEndDate_cc6cbb3e-d1b5-4b76-877a-4bfab28ed31a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_3ce0e324-27a4-4da5-906e-74e27f9dc437" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_19663ab4-a456-4595-9ef0-a80af45873a1" xlink:to="loc_dei_EntityRegistrantName_3ce0e324-27a4-4da5-906e-74e27f9dc437" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_9bd21430-1671-4503-89e8-fc2cd138d72c" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_19663ab4-a456-4595-9ef0-a80af45873a1" xlink:to="loc_dei_EntityIncorporationStateCountryCode_9bd21430-1671-4503-89e8-fc2cd138d72c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_1b714af7-9ac2-4684-a351-f41cc7ef500b" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_19663ab4-a456-4595-9ef0-a80af45873a1" xlink:to="loc_dei_EntityFileNumber_1b714af7-9ac2-4684-a351-f41cc7ef500b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber_ebe7af6d-e11d-4da8-a313-e2ebbc8e9883" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_19663ab4-a456-4595-9ef0-a80af45873a1" xlink:to="loc_dei_EntityTaxIdentificationNumber_ebe7af6d-e11d-4da8-a313-e2ebbc8e9883" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_999e0a08-3eb4-44e8-8f66-47908e20d2e5" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_19663ab4-a456-4595-9ef0-a80af45873a1" xlink:to="loc_dei_EntityAddressAddressLine1_999e0a08-3eb4-44e8-8f66-47908e20d2e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine2_bb504ade-4ea1-49ab-9742-b3508cfd0dd3" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine2"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_19663ab4-a456-4595-9ef0-a80af45873a1" xlink:to="loc_dei_EntityAddressAddressLine2_bb504ade-4ea1-49ab-9742-b3508cfd0dd3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_701a4922-70c6-48c0-812b-b31f4fde2ef9" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_19663ab4-a456-4595-9ef0-a80af45873a1" xlink:to="loc_dei_EntityAddressCityOrTown_701a4922-70c6-48c0-812b-b31f4fde2ef9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince_835d2b2a-fbd9-4dcc-9996-30148b300d05" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressStateOrProvince"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_19663ab4-a456-4595-9ef0-a80af45873a1" xlink:to="loc_dei_EntityAddressStateOrProvince_835d2b2a-fbd9-4dcc-9996-30148b300d05" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_d4ce5f72-96bd-4b6b-b962-60f311d753d4" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_19663ab4-a456-4595-9ef0-a80af45873a1" xlink:to="loc_dei_EntityAddressPostalZipCode_d4ce5f72-96bd-4b6b-b962-60f311d753d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_d6277cb4-9603-4e6a-a5cd-f03a814c3229" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_19663ab4-a456-4595-9ef0-a80af45873a1" xlink:to="loc_dei_CityAreaCode_d6277cb4-9603-4e6a-a5cd-f03a814c3229" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_973d210d-a23c-4037-83fa-bc8418e5e980" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_19663ab4-a456-4595-9ef0-a80af45873a1" xlink:to="loc_dei_LocalPhoneNumber_973d210d-a23c-4037-83fa-bc8418e5e980" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_WrittenCommunications_69e55d54-7559-41f4-bf28-c7e00db5984e" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_WrittenCommunications"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_19663ab4-a456-4595-9ef0-a80af45873a1" xlink:to="loc_dei_WrittenCommunications_69e55d54-7559-41f4-bf28-c7e00db5984e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SolicitingMaterial_5fd5a321-9f4a-407d-b47e-794e0c10ef73" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SolicitingMaterial"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_19663ab4-a456-4595-9ef0-a80af45873a1" xlink:to="loc_dei_SolicitingMaterial_5fd5a321-9f4a-407d-b47e-794e0c10ef73" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementTenderOffer_14e17502-8b60-4c9d-88d8-7bf8f4a42087" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_PreCommencementTenderOffer"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_19663ab4-a456-4595-9ef0-a80af45873a1" xlink:to="loc_dei_PreCommencementTenderOffer_14e17502-8b60-4c9d-88d8-7bf8f4a42087" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementIssuerTenderOffer_00b565ce-17da-4b7f-adae-9613220e34fc" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_PreCommencementIssuerTenderOffer"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_19663ab4-a456-4595-9ef0-a80af45873a1" xlink:to="loc_dei_PreCommencementIssuerTenderOffer_00b565ce-17da-4b7f-adae-9613220e34fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_6264eae4-daa6-44a2-b7e1-490819398a69" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_19663ab4-a456-4595-9ef0-a80af45873a1" xlink:to="loc_dei_Security12bTitle_6264eae4-daa6-44a2-b7e1-490819398a69" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_ae2f7e8d-8505-4daa-86aa-75447407b3c6" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_19663ab4-a456-4595-9ef0-a80af45873a1" xlink:to="loc_dei_TradingSymbol_ae2f7e8d-8505-4daa-86aa-75447407b3c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName_82c640b3-412b-4a49-b933-9015554745ec" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityExchangeName"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_19663ab4-a456-4595-9ef0-a80af45873a1" xlink:to="loc_dei_SecurityExchangeName_82c640b3-412b-4a49-b933-9015554745ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_757b3264-6fc1-46ac-9a09-4b6965fb3569" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_19663ab4-a456-4595-9ef0-a80af45873a1" xlink:to="loc_dei_EntityEmergingGrowthCompany_757b3264-6fc1-46ac-9a09-4b6965fb3569" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_7c00c8b5-9ec2-49bf-bc95-167b5d7d2b26" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_19663ab4-a456-4595-9ef0-a80af45873a1" xlink:to="loc_dei_EntityCentralIndexKey_7c00c8b5-9ec2-49bf-bc95-167b5d7d2b26" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_b5646bab-26ba-40f5-816d-9bb1d809e4c8" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_19663ab4-a456-4595-9ef0-a80af45873a1" xlink:to="loc_dei_AmendmentFlag_b5646bab-26ba-40f5-816d-9bb1d809e4c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentInformationTable_1a102a0e-cdac-425c-b3f5-bd979b9d3920" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentInformationTable"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_19663ab4-a456-4595-9ef0-a80af45873a1" xlink:to="loc_dei_DocumentInformationTable_1a102a0e-cdac-425c-b3f5-bd979b9d3920" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentInformationLineItems_ca27e1be-9d32-4594-8664-4d24308f73e0" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentInformationLineItems"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationTable_1a102a0e-cdac-425c-b3f5-bd979b9d3920" xlink:to="loc_dei_DocumentInformationLineItems_ca27e1be-9d32-4594-8664-4d24308f73e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_54f83273-8ca6-4c64-a892-a0b7b741e9d5" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_ca27e1be-9d32-4594-8664-4d24308f73e0" xlink:to="loc_dei_DocumentPeriodEndDate_54f83273-8ca6-4c64-a892-a0b7b741e9d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>7
<FILENAME>img34400995_0a.jpg
<TEXT>
begin 644 img34400995_0a.jpg
M_]C_X  02D9)1@ ! 0$ W #<  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" "G @8# 2(  A$! Q$!_\0
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M:*\#5C%HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MU2X4Y(Y_Y9J>I[D8]:\V^ ?P=\3_ +9'QJ!O?-_L6&5)M8OE.U+6VSQ$GHS
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MBO+=R,%DD0,I(['!Z5^=_P#P5H^)QN-6\&_#^WF;9;H^LWT6 5+,3' <]=P
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M '>DHGH'[//P!\/?LY_#^W\-Z&GG3,1-?ZA(,27<Y&"[>@[ =A7J-?">I?\
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MOS:_:@^)@^+WQ\\9^)XI%DL[B^:"T=,[6MX@(HVP>FY5!^I-:?[.O[1-_P#
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MRA"%FUO<GE-Y55555&% P!3J**^**/R2_P""J[!?VD-)R<?\4[;]_P#IM/7
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MW]F_]D[QA^T-XHM+6RL9M+\-JV^\UJXB*Q1QC&0F?O.0> .._:O/?BWX:LO
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M444 %%%% !1110 4444 %%%% !1110 4444 )2<=*=24K >7_'SX ^&/VB/
MUSX>\1VX649>RU&)1Y]G-CAT/\UZ$5^5&DWOQ#_X)\_M!I#>,_D*ZFXCB/\
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MQ4/A7]G[XU?'3P?%KGQ'^*VK>$[C5A'<KX?T*)$BM4VC8K<<-P"0.YKD-+^
MEW\#?VS_ ((QW7C36/&/]I1ZNRMJS F#9:-]S'KNY^@K6"]Z?-4N[/36VP'L
M/_!1Q2W[)OB@+P3=6.#Z'[3'@UW?PF_9P\(?#_P7:V5[I-EX@UJY/VS4]7U"
M!9IKR[< R2%F!.">@Z  5PW_  4:_P"34?$O_7W8_P#I5'7TG9_\>D'^XO\
M*N*52<,-!)V5W^@'PW\>_A_:_L^_M<?!SQ]X*L(]*M/%&I#0=8M+=0ENYD94
M#D#^(J[''0&(&O2_V_/'&OZ-\+M$\'>%+E;;Q%XXUF#086\S8XBDSYA5NV3L
M0GT<U!^W)<1?;?@9;;U^TR?$+361,_,5!;)'MDK^=><_\%(_"MUXR^(OP!T>
M.\N-.MM1UR73WOK;[]N\LENJNO\ M ;B/I7;1_?3HRJ/H]?2[0'U!\._V=_
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MTNVN(SN2:&SC5E/J"!Q6\0#U&:PJ2I6M3C;U ^._^"8[ _"/QUM.?^*RO?\
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L@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH __]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>8
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm140551029816736">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Cover<br></strong></div></th>
<th class="th"><div>May 05, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">May  05,  2023<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">OVID THERAPEUTICS INC.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-38085<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">46-5270895<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">441 Ninth Avenue<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">14th Floor<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">New York<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">NY<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">10001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">646<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">661-7661<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre-commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre-commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, par value $0.001 per share<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">OVID<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001636651<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentInformationLineItems', window );"><strong>Document Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">May  05,  2023<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentInformationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentInformationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Section 14a<br> -Number 240<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>9
<FILENAME>ovid-20230505_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xml:lang="en-US"
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2022"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="ovid-20230505.xsd" xlink:type="simple"/>
    <context id="i3959c496a69e480bb832a8e8833578c0_D20230505-20230505">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001636651</identifier>
        </entity>
        <period>
            <startDate>2023-05-05</startDate>
            <endDate>2023-05-05</endDate>
        </period>
    </context>
    <dei:EntityCentralIndexKey
      contextRef="i3959c496a69e480bb832a8e8833578c0_D20230505-20230505"
      id="id3VybDovL2RvY3MudjEvZG9jOjYzMTJiZTdjYmNiYTQ3NjY4YzZlZTM2N2RlOTVhMDQyL3NlYzo2MzEyYmU3Y2JjYmE0NzY2OGM2ZWUzNjdkZTk1YTA0Ml80L2ZyYWc6NzZjMThlNWFiNjY2NDk1MTg2ZDExNWNjYWU5OTQ3YzIvdGFibGU6NmQwZmFlM2I0NmI2NDk4OGE3MWYxMzMyODFhYjY0NTAvdGFibGVyYW5nZTo2ZDBmYWUzYjQ2YjY0OTg4YTcxZjEzMzI4MWFiNjQ1MF8yLTEtMS0xLTI3ODAz_80c9e11a-afc5-49e4-a07d-c27bade4b8fa">0001636651</dei:EntityCentralIndexKey>
    <dei:AmendmentFlag
      contextRef="i3959c496a69e480bb832a8e8833578c0_D20230505-20230505"
      id="id3VybDovL2RvY3MudjEvZG9jOjYzMTJiZTdjYmNiYTQ3NjY4YzZlZTM2N2RlOTVhMDQyL3NlYzo2MzEyYmU3Y2JjYmE0NzY2OGM2ZWUzNjdkZTk1YTA0Ml80L2ZyYWc6NzZjMThlNWFiNjY2NDk1MTg2ZDExNWNjYWU5OTQ3YzIvdGFibGU6NmQwZmFlM2I0NmI2NDk4OGE3MWYxMzMyODFhYjY0NTAvdGFibGVyYW5nZTo2ZDBmYWUzYjQ2YjY0OTg4YTcxZjEzMzI4MWFiNjQ1MF8zLTEtMS0xLTI3ODAz_99a83a5a-883a-4f52-830d-552107c78d1b">false</dei:AmendmentFlag>
    <dei:DocumentType
      contextRef="i3959c496a69e480bb832a8e8833578c0_D20230505-20230505"
      id="id3VybDovL2RvY3MudjEvZG9jOjYzMTJiZTdjYmNiYTQ3NjY4YzZlZTM2N2RlOTVhMDQyL3NlYzo2MzEyYmU3Y2JjYmE0NzY2OGM2ZWUzNjdkZTk1YTA0Ml8xL2ZyYWc6NWMyODM0YjMzOGZiNGY0MmEwMzY2ZjRlMDc1Mzc2NDYvdGV4dHJlZ2lvbjo1YzI4MzRiMzM4ZmI0ZjQyYTAzNjZmNGUwNzUzNzY0Nl8xMjY0_53c4de14-64e7-4f3e-ae21-4a3da1a81312">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate
      contextRef="i3959c496a69e480bb832a8e8833578c0_D20230505-20230505"
      id="id3VybDovL2RvY3MudjEvZG9jOjYzMTJiZTdjYmNiYTQ3NjY4YzZlZTM2N2RlOTVhMDQyL3NlYzo2MzEyYmU3Y2JjYmE0NzY2OGM2ZWUzNjdkZTk1YTA0Ml8xL2ZyYWc6NWMyODM0YjMzOGZiNGY0MmEwMzY2ZjRlMDc1Mzc2NDYvdGV4dHJlZ2lvbjo1YzI4MzRiMzM4ZmI0ZjQyYTAzNjZmNGUwNzUzNzY0Nl81NDk3NTU4MTUxNTc_d48220bf-ee4d-413f-960c-f55a15380742">2023-05-05</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName
      contextRef="i3959c496a69e480bb832a8e8833578c0_D20230505-20230505"
      id="id3VybDovL2RvY3MudjEvZG9jOjYzMTJiZTdjYmNiYTQ3NjY4YzZlZTM2N2RlOTVhMDQyL3NlYzo2MzEyYmU3Y2JjYmE0NzY2OGM2ZWUzNjdkZTk1YTA0Ml8xL2ZyYWc6NWMyODM0YjMzOGZiNGY0MmEwMzY2ZjRlMDc1Mzc2NDYvdGV4dHJlZ2lvbjo1YzI4MzRiMzM4ZmI0ZjQyYTAzNjZmNGUwNzUzNzY0Nl8xMjY2_322babac-0be5-4a8f-bb18-8ea73efc2b1a">OVID THERAPEUTICS INC.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="i3959c496a69e480bb832a8e8833578c0_D20230505-20230505"
      id="id3VybDovL2RvY3MudjEvZG9jOjYzMTJiZTdjYmNiYTQ3NjY4YzZlZTM2N2RlOTVhMDQyL3NlYzo2MzEyYmU3Y2JjYmE0NzY2OGM2ZWUzNjdkZTk1YTA0Ml8xL2ZyYWc6NWMyODM0YjMzOGZiNGY0MmEwMzY2ZjRlMDc1Mzc2NDYvdGFibGU6YWE0Yzg5ZGZlZGU2NGYzODk1YzI0N2YxNTc5NmRmMzYvdGFibGVyYW5nZTphYTRjODlkZmVkZTY0ZjM4OTVjMjQ3ZjE1Nzk2ZGYzNl8wLTAtMS0xLTI3ODAz_00f8d6ac-d88c-4e67-90e7-4d50e79dea0f">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber
      contextRef="i3959c496a69e480bb832a8e8833578c0_D20230505-20230505"
      id="id3VybDovL2RvY3MudjEvZG9jOjYzMTJiZTdjYmNiYTQ3NjY4YzZlZTM2N2RlOTVhMDQyL3NlYzo2MzEyYmU3Y2JjYmE0NzY2OGM2ZWUzNjdkZTk1YTA0Ml8xL2ZyYWc6NWMyODM0YjMzOGZiNGY0MmEwMzY2ZjRlMDc1Mzc2NDYvdGFibGU6YWE0Yzg5ZGZlZGU2NGYzODk1YzI0N2YxNTc5NmRmMzYvdGFibGVyYW5nZTphYTRjODlkZmVkZTY0ZjM4OTVjMjQ3ZjE1Nzk2ZGYzNl8wLTEtMS0xLTI3ODAz_0bac4834-be9d-4f21-b178-4d5823f659dc">001-38085</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber
      contextRef="i3959c496a69e480bb832a8e8833578c0_D20230505-20230505"
      id="id3VybDovL2RvY3MudjEvZG9jOjYzMTJiZTdjYmNiYTQ3NjY4YzZlZTM2N2RlOTVhMDQyL3NlYzo2MzEyYmU3Y2JjYmE0NzY2OGM2ZWUzNjdkZTk1YTA0Ml8xL2ZyYWc6NWMyODM0YjMzOGZiNGY0MmEwMzY2ZjRlMDc1Mzc2NDYvdGFibGU6YWE0Yzg5ZGZlZGU2NGYzODk1YzI0N2YxNTc5NmRmMzYvdGFibGVyYW5nZTphYTRjODlkZmVkZTY0ZjM4OTVjMjQ3ZjE1Nzk2ZGYzNl8wLTItMS0xLTI3ODAz_8e930dc5-23a5-4bb9-aa88-abe9d38f77ae">46-5270895</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="i3959c496a69e480bb832a8e8833578c0_D20230505-20230505"
      id="id3VybDovL2RvY3MudjEvZG9jOjYzMTJiZTdjYmNiYTQ3NjY4YzZlZTM2N2RlOTVhMDQyL3NlYzo2MzEyYmU3Y2JjYmE0NzY2OGM2ZWUzNjdkZTk1YTA0Ml8xL2ZyYWc6NWMyODM0YjMzOGZiNGY0MmEwMzY2ZjRlMDc1Mzc2NDYvdGFibGU6YWE0Yzg5ZGZlZGU2NGYzODk1YzI0N2YxNTc5NmRmMzYvdGFibGVyYW5nZTphYTRjODlkZmVkZTY0ZjM4OTVjMjQ3ZjE1Nzk2ZGYzNl8zLTAtMS0xLTI3ODAzL3RleHRyZWdpb246NzdiZTMwN2I0ZjhkNDJhYmI3NTI3ZDQxOTYxNDgyYmVfNA_e0d16ea0-8ddc-48cb-bdda-553d9d67ce51">441 Ninth Avenue</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2
      contextRef="i3959c496a69e480bb832a8e8833578c0_D20230505-20230505"
      id="id3VybDovL2RvY3MudjEvZG9jOjYzMTJiZTdjYmNiYTQ3NjY4YzZlZTM2N2RlOTVhMDQyL3NlYzo2MzEyYmU3Y2JjYmE0NzY2OGM2ZWUzNjdkZTk1YTA0Ml8xL2ZyYWc6NWMyODM0YjMzOGZiNGY0MmEwMzY2ZjRlMDc1Mzc2NDYvdGFibGU6YWE0Yzg5ZGZlZGU2NGYzODk1YzI0N2YxNTc5NmRmMzYvdGFibGVyYW5nZTphYTRjODlkZmVkZTY0ZjM4OTVjMjQ3ZjE1Nzk2ZGYzNl8zLTAtMS0xLTI3ODAzL3RleHRyZWdpb246NzdiZTMwN2I0ZjhkNDJhYmI3NTI3ZDQxOTYxNDgyYmVfOA_fa90cc61-1c9f-483f-af73-68b713f4c40e">14th Floor</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown
      contextRef="i3959c496a69e480bb832a8e8833578c0_D20230505-20230505"
      id="id3VybDovL2RvY3MudjEvZG9jOjYzMTJiZTdjYmNiYTQ3NjY4YzZlZTM2N2RlOTVhMDQyL3NlYzo2MzEyYmU3Y2JjYmE0NzY2OGM2ZWUzNjdkZTk1YTA0Ml8xL2ZyYWc6NWMyODM0YjMzOGZiNGY0MmEwMzY2ZjRlMDc1Mzc2NDYvdGFibGU6YWE0Yzg5ZGZlZGU2NGYzODk1YzI0N2YxNTc5NmRmMzYvdGFibGVyYW5nZTphYTRjODlkZmVkZTY0ZjM4OTVjMjQ3ZjE1Nzk2ZGYzNl8zLTAtMS0xLTI3ODAzL3RleHRyZWdpb246NzdiZTMwN2I0ZjhkNDJhYmI3NTI3ZDQxOTYxNDgyYmVfMTE_ef74eb2b-0191-4035-9006-cf219e801e5c">New York</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="i3959c496a69e480bb832a8e8833578c0_D20230505-20230505"
      id="id3VybDovL2RvY3MudjEvZG9jOjYzMTJiZTdjYmNiYTQ3NjY4YzZlZTM2N2RlOTVhMDQyL3NlYzo2MzEyYmU3Y2JjYmE0NzY2OGM2ZWUzNjdkZTk1YTA0Ml8xL2ZyYWc6NWMyODM0YjMzOGZiNGY0MmEwMzY2ZjRlMDc1Mzc2NDYvdGFibGU6YWE0Yzg5ZGZlZGU2NGYzODk1YzI0N2YxNTc5NmRmMzYvdGFibGVyYW5nZTphYTRjODlkZmVkZTY0ZjM4OTVjMjQ3ZjE1Nzk2ZGYzNl8zLTAtMS0xLTI3ODAzL3RleHRyZWdpb246NzdiZTMwN2I0ZjhkNDJhYmI3NTI3ZDQxOTYxNDgyYmVfMTU_d9d2e7c1-3b33-4f69-87db-1d22a53ece9d">NY</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="i3959c496a69e480bb832a8e8833578c0_D20230505-20230505"
      id="id3VybDovL2RvY3MudjEvZG9jOjYzMTJiZTdjYmNiYTQ3NjY4YzZlZTM2N2RlOTVhMDQyL3NlYzo2MzEyYmU3Y2JjYmE0NzY2OGM2ZWUzNjdkZTk1YTA0Ml8xL2ZyYWc6NWMyODM0YjMzOGZiNGY0MmEwMzY2ZjRlMDc1Mzc2NDYvdGFibGU6YWE0Yzg5ZGZlZGU2NGYzODk1YzI0N2YxNTc5NmRmMzYvdGFibGVyYW5nZTphYTRjODlkZmVkZTY0ZjM4OTVjMjQ3ZjE1Nzk2ZGYzNl8zLTItMS0xLTI3ODAzL3RleHRyZWdpb246YzYyZjMzNWUxZWNhNGEyZGFkZjFhNDgzNWNmMzgzYjhfNA_67312142-3cc5-47f1-ae4c-3858d3d16f58">10001</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="i3959c496a69e480bb832a8e8833578c0_D20230505-20230505"
      id="id3VybDovL2RvY3MudjEvZG9jOjYzMTJiZTdjYmNiYTQ3NjY4YzZlZTM2N2RlOTVhMDQyL3NlYzo2MzEyYmU3Y2JjYmE0NzY2OGM2ZWUzNjdkZTk1YTA0Ml8xL2ZyYWc6NWMyODM0YjMzOGZiNGY0MmEwMzY2ZjRlMDc1Mzc2NDYvdGV4dHJlZ2lvbjo1YzI4MzRiMzM4ZmI0ZjQyYTAzNjZmNGUwNzUzNzY0Nl8xMjYz_2a53580e-50ec-47b1-aa19-a2d0634e7cf4">646</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="i3959c496a69e480bb832a8e8833578c0_D20230505-20230505"
      id="id3VybDovL2RvY3MudjEvZG9jOjYzMTJiZTdjYmNiYTQ3NjY4YzZlZTM2N2RlOTVhMDQyL3NlYzo2MzEyYmU3Y2JjYmE0NzY2OGM2ZWUzNjdkZTk1YTA0Ml8xL2ZyYWc6NWMyODM0YjMzOGZiNGY0MmEwMzY2ZjRlMDc1Mzc2NDYvdGV4dHJlZ2lvbjo1YzI4MzRiMzM4ZmI0ZjQyYTAzNjZmNGUwNzUzNzY0Nl8xMjY1_96ced9a4-d8df-46dc-94a8-d1b87aa3fcc3">661-7661</dei:LocalPhoneNumber>
    <dei:WrittenCommunications
      contextRef="i3959c496a69e480bb832a8e8833578c0_D20230505-20230505"
      id="id3VybDovL2RvY3MudjEvZG9jOjYzMTJiZTdjYmNiYTQ3NjY4YzZlZTM2N2RlOTVhMDQyL3NlYzo2MzEyYmU3Y2JjYmE0NzY2OGM2ZWUzNjdkZTk1YTA0Ml8xL2ZyYWc6NWMyODM0YjMzOGZiNGY0MmEwMzY2ZjRlMDc1Mzc2NDYvdGFibGU6YmE0ZTJiMDEzMzhlNGY4NDlhZDJkOTU4MTVkZDQ4OTYvdGFibGVyYW5nZTpiYTRlMmIwMTMzOGU0Zjg0OWFkMmQ5NTgxNWRkNDg5Nl8wLTAtMS0xLTI3ODAz_aa8ee493-a3a5-45e4-81ce-1e919d0732d6">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial
      contextRef="i3959c496a69e480bb832a8e8833578c0_D20230505-20230505"
      id="id3VybDovL2RvY3MudjEvZG9jOjYzMTJiZTdjYmNiYTQ3NjY4YzZlZTM2N2RlOTVhMDQyL3NlYzo2MzEyYmU3Y2JjYmE0NzY2OGM2ZWUzNjdkZTk1YTA0Ml8xL2ZyYWc6NWMyODM0YjMzOGZiNGY0MmEwMzY2ZjRlMDc1Mzc2NDYvdGFibGU6YmE0ZTJiMDEzMzhlNGY4NDlhZDJkOTU4MTVkZDQ4OTYvdGFibGVyYW5nZTpiYTRlMmIwMTMzOGU0Zjg0OWFkMmQ5NTgxNWRkNDg5Nl8yLTAtMS0xLTI3ODAz_43ec5151-5468-4db3-a8a2-b31689957a5c">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer
      contextRef="i3959c496a69e480bb832a8e8833578c0_D20230505-20230505"
      id="id3VybDovL2RvY3MudjEvZG9jOjYzMTJiZTdjYmNiYTQ3NjY4YzZlZTM2N2RlOTVhMDQyL3NlYzo2MzEyYmU3Y2JjYmE0NzY2OGM2ZWUzNjdkZTk1YTA0Ml8xL2ZyYWc6NWMyODM0YjMzOGZiNGY0MmEwMzY2ZjRlMDc1Mzc2NDYvdGFibGU6YmE0ZTJiMDEzMzhlNGY4NDlhZDJkOTU4MTVkZDQ4OTYvdGFibGVyYW5nZTpiYTRlMmIwMTMzOGU0Zjg0OWFkMmQ5NTgxNWRkNDg5Nl80LTAtMS0xLTI3ODAz_f311148b-32bb-40bd-9ee2-f2330e4bf609">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer
      contextRef="i3959c496a69e480bb832a8e8833578c0_D20230505-20230505"
      id="id3VybDovL2RvY3MudjEvZG9jOjYzMTJiZTdjYmNiYTQ3NjY4YzZlZTM2N2RlOTVhMDQyL3NlYzo2MzEyYmU3Y2JjYmE0NzY2OGM2ZWUzNjdkZTk1YTA0Ml8xL2ZyYWc6NWMyODM0YjMzOGZiNGY0MmEwMzY2ZjRlMDc1Mzc2NDYvdGFibGU6YmE0ZTJiMDEzMzhlNGY4NDlhZDJkOTU4MTVkZDQ4OTYvdGFibGVyYW5nZTpiYTRlMmIwMTMzOGU0Zjg0OWFkMmQ5NTgxNWRkNDg5Nl82LTAtMS0xLTI3ODAz_054196f3-52c9-4b1f-a4c8-a7bb11bcd8df">false</dei:PreCommencementIssuerTenderOffer>
    <dei:Security12bTitle
      contextRef="i3959c496a69e480bb832a8e8833578c0_D20230505-20230505"
      id="id3VybDovL2RvY3MudjEvZG9jOjYzMTJiZTdjYmNiYTQ3NjY4YzZlZTM2N2RlOTVhMDQyL3NlYzo2MzEyYmU3Y2JjYmE0NzY2OGM2ZWUzNjdkZTk1YTA0Ml8xL2ZyYWc6NWMyODM0YjMzOGZiNGY0MmEwMzY2ZjRlMDc1Mzc2NDYvdGFibGU6MzMzMWIwNzJjNGVmNDBmODk0NzlkNWI2NmY5NDVmYmYvdGFibGVyYW5nZTozMzMxYjA3MmM0ZWY0MGY4OTQ3OWQ1YjY2Zjk0NWZiZl8xLTAtMS0xLTI3ODAz_58b0c82e-9db7-4cc7-8663-6bc46381a9bc">Common Stock, par value $0.001 per share</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="i3959c496a69e480bb832a8e8833578c0_D20230505-20230505"
      id="id3VybDovL2RvY3MudjEvZG9jOjYzMTJiZTdjYmNiYTQ3NjY4YzZlZTM2N2RlOTVhMDQyL3NlYzo2MzEyYmU3Y2JjYmE0NzY2OGM2ZWUzNjdkZTk1YTA0Ml8xL2ZyYWc6NWMyODM0YjMzOGZiNGY0MmEwMzY2ZjRlMDc1Mzc2NDYvdGFibGU6MzMzMWIwNzJjNGVmNDBmODk0NzlkNWI2NmY5NDVmYmYvdGFibGVyYW5nZTozMzMxYjA3MmM0ZWY0MGY4OTQ3OWQ1YjY2Zjk0NWZiZl8xLTItMS0xLTI3ODAz_a256b228-71bf-4853-9e68-b8a2430b4474">OVID</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="i3959c496a69e480bb832a8e8833578c0_D20230505-20230505"
      id="id3VybDovL2RvY3MudjEvZG9jOjYzMTJiZTdjYmNiYTQ3NjY4YzZlZTM2N2RlOTVhMDQyL3NlYzo2MzEyYmU3Y2JjYmE0NzY2OGM2ZWUzNjdkZTk1YTA0Ml8xL2ZyYWc6NWMyODM0YjMzOGZiNGY0MmEwMzY2ZjRlMDc1Mzc2NDYvdGFibGU6MzMzMWIwNzJjNGVmNDBmODk0NzlkNWI2NmY5NDVmYmYvdGFibGVyYW5nZTozMzMxYjA3MmM0ZWY0MGY4OTQ3OWQ1YjY2Zjk0NWZiZl8xLTQtMS0xLTI3ODAz_5f24d9ac-a100-49c9-8373-88574baf2207">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityEmergingGrowthCompany
      contextRef="i3959c496a69e480bb832a8e8833578c0_D20230505-20230505"
      id="id3VybDovL2RvY3MudjEvZG9jOjYzMTJiZTdjYmNiYTQ3NjY4YzZlZTM2N2RlOTVhMDQyL3NlYzo2MzEyYmU3Y2JjYmE0NzY2OGM2ZWUzNjdkZTk1YTA0Ml8xL2ZyYWc6NWMyODM0YjMzOGZiNGY0MmEwMzY2ZjRlMDc1Mzc2NDYvdGV4dHJlZ2lvbjo1YzI4MzRiMzM4ZmI0ZjQyYTAzNjZmNGUwNzUzNzY0Nl8xMjU2_03a8d9e4-5f08-4670-86b1-bde8d70c5d12">false</dei:EntityEmergingGrowthCompany>
    <dei:DocumentPeriodEndDate
      contextRef="i3959c496a69e480bb832a8e8833578c0_D20230505-20230505"
      id="id3VybDovL2RvY3MudjEvZG9jOjYzMTJiZTdjYmNiYTQ3NjY4YzZlZTM2N2RlOTVhMDQyL3NlYzo2MzEyYmU3Y2JjYmE0NzY2OGM2ZWUzNjdkZTk1YTA0Ml8xMy9mcmFnOjY0MDYxZTQzYjhjNDQzZmJiNjQ5YTBjYWQ4MGYwODQ0L3RleHRyZWdpb246NjQwNjFlNDNiOGM0NDNmYmI2NDlhMGNhZDgwZjA4NDRfNTQ5NzU1ODE0MTAw_d48220bf-ee4d-413f-960c-f55a15380742">2023-05-05</dei:DocumentPeriodEndDate>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>10
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M*T-LVC-K[M[@O_OPLU9Z5E)W*]6+7C-FR&L2"]USUL:DMXV&#M<LH?I*IDS
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M&S*E]IL;^PLCTWQ#82&-D4E^NF84+-B^ ,^74IJW"[M'46PQ]?\%4$L#!!0
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M8U!R;W!S+V-O<F4N>&UL4$L! A0#%     @ "D*E5IE<G",0!@  G"<  !,
M             ( !S $  'AL+W1H96UE+W1H96UE,2YX;6Q02P$"% ,4
M"  *0J56[U;CY8P$  !N$@  &               @($-"   >&PO=V]R:W-H
M965T<R]S:&5E=#$N>&UL4$L! A0#%     @ "D*E5I^@&_"Q @  X@P   T
M             ( !SPP  'AL+W-T>6QE<RYX;6Q02P$"% ,4    "  *0J56
MEXJ[',     3 @  "P              @ &K#P  7W)E;',O+G)E;'-02P$"
M% ,4    "  *0J56JL0B%C,!   B @  #P              @ &4$   >&PO
M=V]R:V)O;VLN>&UL4$L! A0#%     @ "D*E5B0>FZ*M    ^ $  !H
M         ( !]!$  'AL+U]R96QS+W=O<FMB;V]K+GAM;"YR96QS4$L! A0#
M%     @ "D*E5F60>9(9 0  SP,  !,              ( !V1(  %M#;VYT
D96YT7U1Y<&5S72YX;6Q02P4&      D "0 ^ @  (Q0

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.23.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>1</ContextCount>
  <ElementCount>23</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>0</UnitCount>
  <MyReports>
    <Report instance="ovid-20230505.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0000001 - Document - Cover</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ovidrx.com/role/Cover</Role>
      <ShortName>Cover</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <Logs>
    <Log type="Warning">[dq-0540-DocumentPeriodEndDate-Value] In submission type 8-K, DocumentPeriodEndDate value "2023-05-05", is not equivalent to header element periodOfReport value "03-31-2023" in the Required Context. ovid-20230505.htm 4</Log>
  </Logs>
  <InputFiles>
    <File doctype="8-K" original="ovid-20230505.htm">ovid-20230505.htm</File>
    <File>ovid-20230505.xsd</File>
    <File>ovid-20230505_def.xml</File>
    <File>ovid-20230505_lab.xml</File>
    <File>ovid-20230505_pre.xml</File>
    <File>ovid2023q1exhibit991.htm</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="24">http://xbrl.sec.gov/dei/2022</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>16
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "ovid-20230505.htm": {
   "axisCustom": 0,
   "axisStandard": 0,
   "baseTaxonomies": {
    "http://xbrl.sec.gov/dei/2022": 24
   },
   "contextCount": 1,
   "dts": {
    "definitionLink": {
     "local": [
      "ovid-20230505_def.xml"
     ]
    },
    "inline": {
     "local": [
      "ovid-20230505.htm"
     ]
    },
    "labelLink": {
     "local": [
      "ovid-20230505_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "ovid-20230505_pre.xml"
     ]
    },
    "schema": {
     "local": [
      "ovid-20230505.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://xbrl.sec.gov/dei/2022/dei-2022.xsd"
     ]
    }
   },
   "elementCount": 26,
   "entityCount": 1,
   "hidden": {
    "http://xbrl.sec.gov/dei/2022": 2,
    "total": 2
   },
   "keyCustom": 0,
   "keyStandard": 23,
   "memberCustom": 0,
   "memberStandard": 0,
   "nsprefix": "ovid",
   "nsuri": "http://www.ovidrx.com/20230505",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ovid-20230505.htm",
      "contextRef": "i3959c496a69e480bb832a8e8833578c0_D20230505-20230505",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "0000001 - Document - Cover",
     "menuCat": "Cover",
     "order": "1",
     "role": "http://www.ovidrx.com/role/Cover",
     "shortName": "Cover",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ovid-20230505.htm",
      "contextRef": "i3959c496a69e480bb832a8e8833578c0_D20230505-20230505",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 0,
   "tag": {
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.ovidrx.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code",
        "terseLabel": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.ovidrx.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "xbrltype": "stringItemType"
    },
    "dei_DocumentInformationLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Document Information [Line Items]",
        "terseLabel": "Document Information [Line Items]"
       }
      }
     },
     "localname": "DocumentInformationLineItems",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.ovidrx.com/role/Cover"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_DocumentInformationTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Container to support the formal attachment of each official or unofficial, public or private document as part of a submission package.",
        "label": "Document Information [Table]",
        "terseLabel": "Document Information [Table]"
       }
      }
     },
     "localname": "DocumentInformationTable",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.ovidrx.com/role/Cover"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.ovidrx.com/role/Cover"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type",
        "terseLabel": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.ovidrx.com/role/Cover"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One",
        "terseLabel": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.ovidrx.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressAddressLine2": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 2 such as Street or Suite number",
        "label": "Entity Address, Address Line Two",
        "terseLabel": "Entity Address, Address Line Two"
       }
      }
     },
     "localname": "EntityAddressAddressLine2",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.ovidrx.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town",
        "terseLabel": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.ovidrx.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.ovidrx.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province",
        "terseLabel": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.ovidrx.com/role/Cover"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.ovidrx.com/role/Cover"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.ovidrx.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number",
        "terseLabel": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.ovidrx.com/role/Cover"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code",
        "terseLabel": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.ovidrx.com/role/Cover"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.ovidrx.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number",
        "terseLabel": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.ovidrx.com/role/Cover"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.ovidrx.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "auth_ref": [
      "r3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.",
        "label": "Pre-commencement Issuer Tender Offer",
        "terseLabel": "Pre-commencement Issuer Tender Offer"
       }
      }
     },
     "localname": "PreCommencementIssuerTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.ovidrx.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_PreCommencementTenderOffer": {
     "auth_ref": [
      "r4"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.",
        "label": "Pre-commencement Tender Offer",
        "terseLabel": "Pre-commencement Tender Offer"
       }
      }
     },
     "localname": "PreCommencementTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.ovidrx.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security",
        "terseLabel": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.ovidrx.com/role/Cover"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name",
        "terseLabel": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.ovidrx.com/role/Cover"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_SolicitingMaterial": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.",
        "label": "Soliciting Material",
        "terseLabel": "Soliciting Material"
       }
      }
     },
     "localname": "SolicitingMaterial",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.ovidrx.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.ovidrx.com/role/Cover"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "dei_WrittenCommunications": {
     "auth_ref": [
      "r6"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.",
        "label": "Written Communications",
        "terseLabel": "Written Communications"
       }
      }
     },
     "localname": "WrittenCommunications",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.ovidrx.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    }
   },
   "unitCount": 0
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r1": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r2": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r3": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13e",
   "Subsection": "4c",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r4": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14d",
   "Subsection": "2b",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r5": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14a",
   "Subsection": "12",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r6": {
   "Name": "Securities Act",
   "Number": "230",
   "Publisher": "SEC",
   "Section": "425",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  }
 },
 "version": "2.2"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>17
<FILENAME>0001628280-23-015996-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001628280-23-015996-xbrl.zip
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M"4-=5R3X%)7%"XR,QBS) Y;90[X198M>^T86"4IQME\/[\_B(UF#* >\'/.
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M+T2<KN_X*;*L(A%D*Q-A]H=Q+-S@LS=%1#*\^640,61V$V2>#A"Z@:ESD,V
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MVY8:/=-3W3LSVGMH'A_]!%!+ P04    "  *0J56@RDPFE0+   -:0  %0
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MO'@"G*[%4G];HD\(?*TZ_4WP!5C0J+36;&7G$T4!.FONK<N4;P6!?_"*P8$
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MIN&;_P=02P$"% ,4    "  *0J56YH2W1B46  !+FP  $0
M@ $     ;W9I9"TR,#(S,#4P-2YH=&U02P$"% ,4    "  *0J56!ZB/"' "
M  !F"   $0              @ %4%@  ;W9I9"TR,#(S,#4P-2YX<V102P$"
M% ,4    "  *0J56Y]#I<PH#  !)"P  %0              @ 'S&   ;W9I
M9"TR,#(S,#4P-5]D968N>&UL4$L! A0#%     @ "D*E5H,I,)I4"P  #6D
M !4              ( !,!P  &]V:60M,C R,S U,#5?;&%B+GAM;%!+ 0(4
M Q0    (  I"I5;'(K)S9@<  %(Y   5              "  ;<G  !O=FED
M+3(P,C,P-3 U7W!R92YX;6Q02P$"% ,4    "  *0J56].B1,HL>   [X@
M&               @ %0+P  ;W9I9#(P,C-Q,65X:&EB:70Y.3$N:'1M4$L%
3!@     &  8 C0$  !%.      $!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
